65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in COPD Assessment Test (CAT) Score at Week 12 — -6.8 Scores on a scale
Autoimmune Diseases
Primary: Change-from-baseline QT Interval Corrected for Heart Rate Using Fridericia's Method (QTcF) — 1.5; 0.9 msec
Cervical Cancer
Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants
Chronic Pain
Primary: Patient-reported Pain Level Pre Versus Post-VR Session — 6.6; 5.1 score on a scale
Hypoglycemia · Cognition
Primary: Assessment of Immediate Verbal Memory — 50; 48 RAVLT scores on a scale (range 0 to 69) — p=0.90
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose of 5-azacytidine in the Combination of Nivolumab With Dihydro-5-azacytidine — 75; 75; 75 Mg/m^2
Healthy
Primary: Number of Participants With Adverse Events (AEs) — 0; 0; 1; 1 Participants
Safety Issues · Tolerance
Primary: Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) — 50.0; 33.3; 83.3; 16.7 Percentage of participants
Arthritis
Primary: Device Survival: Kaplan-Meir Estimate — 98.47 percentage of participants
Musculoskeletal Pain
Primary: Pain Severity — -2.18; -0.60 score on a scale — p=<0.001
Alzheimer Disease · Alzheimer Dementia · Age-Related Memory Disorders
Primary: Adjusted Wayfinding Speed (Feet Per Second) — 2.32; 2.87; 2.33; 1.83 feet per second — p=<.01
Patient Experience · Medical Emergencies · Mortality
Primary: Patient Experiences, NORPEQ — 78.7; 80.9 units on a scale
Hidradenitis Suppurativa
Primary: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 — -3.61; -2.42 ANs — p=0.0215
Malignant Solid Tumor · Lymphomas
Primary: Number of Patients Who Had an Adverse Events — 25 Participants
Onychomycosis · Tinea Pedis
Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates